Lobbying Activity Report

5735-42758

Organization: Otsuka Canada Pharmaceuticals Inc
Associated registration: 10833-5735-2
Lobbying Activity date: 2025-05-16
Arranged a meeting: No
Posted date: 2025-05-23

In-house lobbyists who participated in the lobbying activity: Maxime Rouleau
Senior Public Office Holders who were lobbied in this activity: Susan Bouma, Executive Director
Clinical Services and Evaluation Branch, Health

John Capelli, Executive Director
Pharmaceutical Policy, Legislation & Engagement Branch, Health

Tijana Fazlagic, Executive Director
PharmaCare Benefits Branch, Health

Sarah Pugh, Executive Director
Integrated Health Services, Planning& Systems, Health

Ian Rongve, ADM
Strategic Innovation, Health

Rebecca Watt, director laboratory services
Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Through Innovative Medicines of Canada (IMC) to further promote the contributions and positive impact of the pharmaceutical industry in British Columbia and to increase awareness of the value of innovative therapies on the healthcare system.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
 
Senior officer who filed this Lobbying Activity Report: Michael Laranjo
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Return to Registration for Western Canada Wilderness Committee
Date Modified: